Research

Jump to: Review

29 pages, 8367 KiB

Open AccessArticle

Effective Cellular Transport of Ortho-Halogenated Sulfonamide Derivatives of Metformin Is Related to Improved Antiproliferative Activity and Apoptosis Induction in MCF-7 Cells

by Magdalena Markowicz-Piasecka, Ibrahim Komeil, Johanna Huttunen, Joanna Sikora and Kristiina M. Huttunen

Int. J. Mol. Sci. 2020, 21(7), 2389; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21072389 - 30 Mar 2020

Cited by 7 | Viewed by 2459

Abstract

Metformin is a substrate for plasma membrane monoamine transporters (PMAT) and organic cation transporters (OCTs); therefore, the expression of these transporters and interactions between them may affect the uptake of metformin into tumor cells and its anticancer efficacy. The aim of this study [...] Read more.

Metformin is a substrate for plasma membrane monoamine transporters (PMAT) and organic cation transporters (OCTs); therefore, the expression of these transporters and interactions between them may affect the uptake of metformin into tumor cells and its anticancer efficacy. The aim of this study was to evaluate how chemical modification of metformin scaffold into benzene sulfonamides with halogen substituents (compounds 1–9) may affect affinity towards OCTs, cellular uptake in two breast cancer cell lines (MCF-7 and MDA-MB-231) and antiproliferative efficacy of metformin. The uptake of most sulfonamides was more efficient in MCF-7 cells than in MDA-MB-231 cells. The presence of a chlorine atom in the aromatic ring contributed to the highest uptake in MCF-7 cells. For instance, the uptake of compound 1 with o-chloro substituent in MCF-7 cells was 1.79 ± 0.79 nmol/min/mg protein, while in MDA-MB-231 cells, the uptake was considerably lower (0.005 ± 0.0005 nmol/min/mg protein). The elevated uptake of tested compounds in MCF-7 was accompanied by high antiproliferative activity, with compound 1 being the most active (IC₅₀ = 12.6 ± 1.2 µmol/L). Further studies showed that inhibition of MCF-7 growth is associated with the induction of early and late apoptosis and cell cycle arrest at the G0/G1 phase. In summary, the chemical modification of the biguanide backbone into halogenated sulfonamides leads to improved transporter-mediated cellular uptake in MCF-7 and contributes to the greater antiproliferative potency of studied compounds through apoptosis induction and cell cycle arrest. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

Review

Jump to: Research

17 pages, 947 KiB

Open AccessReview

The Hormetic Effect of Metformin: “Less Is More”?

by Isabella Panfoli, Alessandra Puddu, Nadia Bertola, Silvia Ravera and Davide Maggi

Int. J. Mol. Sci. 2021, 22(12), 6297; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22126297 - 11 Jun 2021

Cited by 13 | Viewed by 4554

Abstract

Metformin (MTF) is the first-line therapy for type 2 diabetes (T2DM). The euglycemic effect of MTF is due to the inhibition of hepatic glucose production. Literature reports that the principal molecular mechanism of MTF is the activation of 5′-AMP-activated protein kinase (AMPK) due [...] Read more.

Metformin (MTF) is the first-line therapy for type 2 diabetes (T2DM). The euglycemic effect of MTF is due to the inhibition of hepatic glucose production. Literature reports that the principal molecular mechanism of MTF is the activation of 5′-AMP-activated protein kinase (AMPK) due to the decrement of ATP intracellular content consequent to the inhibition of Complex I, although this effect is obtained only at millimolar concentrations. Conversely, micromolar MTF seems to activate the mitochondrial electron transport chain, increasing ATP production and limiting oxidative stress. This evidence sustains the idea that MTF exerts a hormetic effect based on its concentration in the target tissue. Therefore, in this review we describe the effects of MTF on T2DM on the principal target organs, such as liver, gut, adipose tissue, endothelium, heart, and skeletal muscle. In particular, data indicate that all organs, except the gut, accumulate MTF in the micromolar range when administered in therapeutic doses, unmasking molecular mechanisms that do not depend on Complex I inhibition. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Graphical abstract

17 pages, 990 KiB

Open AccessReview

Beneficial Effects of Metformin on the Central Nervous System, with a Focus on Epilepsy and Lafora Disease

by Pascual Sanz, José Maria Serratosa and Marina P. Sánchez

Int. J. Mol. Sci. 2021, 22(10), 5351; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22105351 - 19 May 2021

Cited by 16 | Viewed by 4524

Abstract

Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D). Interestingly, the therapeutic potential of metformin expands its prescribed use as an anti-diabetic drug. In this sense, it has been described [...] Read more.

Metformin is a drug in the family of biguanide compounds that is widely used in the treatment of type 2 diabetes (T2D). Interestingly, the therapeutic potential of metformin expands its prescribed use as an anti-diabetic drug. In this sense, it has been described that metformin administration has beneficial effects on different neurological conditions. In this work, we review the beneficial effects of this drug as a neuroprotective agent in different neurological diseases, with a special focus on epileptic disorders and Lafora disease, a particular type of progressive myoclonus epilepsy. In addition, we review the different proposed mechanisms of action of metformin to understand its function at the neurological level. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

21 pages, 769 KiB

Open AccessReview

Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC

by Yueqi Zhang, Hongbing Wang and Hua Xiao

Int. J. Mol. Sci. 2021, 22(9), 5016; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22095016 - 09 May 2021

Cited by 34 | Viewed by 6478

Abstract

Nonalcoholic fatty liver disease (NAFLD) is strongly linked to the global epidemic of obesity and type 2 diabetes mellitus (T2DM). Notably, NAFLD can progress from the mildest form of simple steatosis to nonalcoholic steatohepatitis (NASH) that increases the risk for hepatocellular carcinoma (HCC), [...] Read more.

Nonalcoholic fatty liver disease (NAFLD) is strongly linked to the global epidemic of obesity and type 2 diabetes mellitus (T2DM). Notably, NAFLD can progress from the mildest form of simple steatosis to nonalcoholic steatohepatitis (NASH) that increases the risk for hepatocellular carcinoma (HCC), which is a malignancy with a dismal prognosis and rising incidence in the United States and other developed counties, possibly due to the epidemic of NAFLD. Metformin, the first-line drug for T2DM, has been suggested to reduce risks for several types of cancers including HCC and protect against NASH-related HCC, as revealed by epidemical studies on humans and preclinical studies on animal models. This review focuses on the pathogenesis of NASH-related HCC and the mechanisms by which metformin inhibits the initiation and progression of NASH-related HCC. Since the functional role of immune cells in liver homeostasis and pathogenesis is increasingly appreciated in developing anti-cancer therapies on liver malignancies, we discuss both the traditional targets of metformin in hepatocytes and the recently defined effects of metformin on immune cells. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

26 pages, 828 KiB

Open AccessReview

The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus

by Chae Bin Lee, Soon Uk Chae, Seong Jun Jo, Ui Min Jerng and Soo Kyung Bae

Int. J. Mol. Sci. 2021, 22(7), 3566; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22073566 - 30 Mar 2021

Cited by 61 | Viewed by 9003

Abstract

Metformin is the first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM); however, its mechanism of modulating glucose metabolism is elusive. Recent advances have identified the gut as a potential target of metformin. As patients with metabolic disorders exhibit dysbiosis, the gut microbiome [...] Read more.

Metformin is the first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM); however, its mechanism of modulating glucose metabolism is elusive. Recent advances have identified the gut as a potential target of metformin. As patients with metabolic disorders exhibit dysbiosis, the gut microbiome has garnered interest as a potential target for metabolic disease. Henceforth, studies have focused on unraveling the relationship of metabolic disorders with the human gut microbiome. According to various metagenome studies, gut dysbiosis is evident in T2DM patients. Besides this, alterations in the gut microbiome were also observed in the metformin-treated T2DM patients compared to the non-treated T2DM patients. Thus, several studies on rodents have suggested potential mechanisms interacting with the gut microbiome, including regulation of glucose metabolism, an increase in short-chain fatty acids, strengthening intestinal permeability against lipopolysaccharides, modulating the immune response, and interaction with bile acids. Furthermore, human studies have demonstrated evidence substantiating the hypotheses based on rodent studies. This review discusses the current knowledge of how metformin modulates T2DM with respect to the gut microbiome and discusses the prospect of harnessing this mechanism in treating T2DM. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

13 pages, 1005 KiB

Open AccessReview

Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History

by Hideaki Kaneto, Tomohiko Kimura, Atsushi Obata, Masashi Shimoda and Kohei Kaku

Int. J. Mol. Sci. 2021, 22(5), 2596; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22052596 - 05 Mar 2021

Cited by 35 | Viewed by 10608

Abstract

While there are various kinds of drugs for type 2 diabetes mellitus at present, in this review article, we focus on metformin which is an insulin sensitizer and is often used as a first-choice drug worldwide. Metformin mainly activates adenosine monophosphate-activated protein kinase [...] Read more.

While there are various kinds of drugs for type 2 diabetes mellitus at present, in this review article, we focus on metformin which is an insulin sensitizer and is often used as a first-choice drug worldwide. Metformin mainly activates adenosine monophosphate-activated protein kinase (AMPK) in the liver which leads to suppression of fatty acid synthesis and gluconeogenesis. Metformin activates AMPK in skeletal muscle as well, which increases translocation of glucose transporter 4 to the cell membrane and thereby increases glucose uptake. Further, metformin suppresses glucagon signaling in the liver by suppressing adenylate cyclase which leads to suppression of gluconeogenesis. In addition, metformin reduces autophagy failure observed in pancreatic β-cells under diabetic conditions. Furthermore, it is known that metformin alters the gut microbiome and facilitates the transport of glucose from the circulation into excrement. It is also known that metformin reduces food intake and lowers body weight by increasing circulating levels of the peptide hormone growth/differentiation factor 15 (GDF15). Furthermore, much attention has been drawn to the fact that the frequency of various cancers is lower in subjects taking metformin. Metformin suppresses the mechanistic target of rapamycin (mTOR) by activating AMPK in pre-neoplastic cells, which leads to suppression of cell growth and an increase in apoptosis in pre-neoplastic cells. It has been shown recently that metformin consumption potentially influences the mortality in patients with type 2 diabetes mellitus and coronavirus infectious disease (COVID-19). Taken together, metformin is an old drug, but multifaceted mechanisms of action of metformin have been unraveled one after another in its long history. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

13 pages, 288 KiB

Open AccessReview

A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders

by Ji-Eun Chang and Min Sik Choi

Int. J. Mol. Sci. 2020, 21(23), 8960; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21238960 - 25 Nov 2020

Cited by 21 | Viewed by 7024

Abstract

Due to its anti-hyperglycemic effect, metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a very wide range of pharmacological properties and reports of its therapeutic effect on [...] Read more.

Due to its anti-hyperglycemic effect, metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are obese. However, metformin is a drug with a very wide range of pharmacological properties and reports of its therapeutic effect on diseases including inflammation and cancer are increasing. Numerous research groups have reported that metformin has beneficial effects on a variety of inflammatory skin disorders including psoriasis, acanthosis nigricans, acne, hidradenitis suppurativa, and allergic contact dermatitis. According to these reports, in addition to the well-known action of metformin, that is, its anti-hyperglycemic effect, NF-kB inhibition and the resulting alteration to the cytokine network may be the potential targets of metformin. Its anti-hyperandrogenism effect has also been confirmed as the major action of metformin in some inflammatory skin diseases. Moreover, novel regulatory mechanisms, including autophagy and antioxidant processes, have been suggested as promising mechanisms of action for metformin in inflammatory skin disorders. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Graphical abstract

16 pages, 803 KiB

Open AccessReview

Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review

by Hyun Kyu Ahn, Young Hwa Lee and Kyo Chul Koo

Int. J. Mol. Sci. 2020, 21(22), 8540; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21228540 - 12 Nov 2020

Cited by 46 | Viewed by 5227

Abstract

Metformin, an oral biguanide used for first-line treatment of type 2 diabetes mellitus, has attracted attention for its anti-proliferative and anti-cancer effects in several solid tumors, including prostate cancer (PCa). Liver kinase B1 (LKB1) and adenosine monophosphate-activated protein kinase (AMPK) activation, inhibition of [...] Read more.

Metformin, an oral biguanide used for first-line treatment of type 2 diabetes mellitus, has attracted attention for its anti-proliferative and anti-cancer effects in several solid tumors, including prostate cancer (PCa). Liver kinase B1 (LKB1) and adenosine monophosphate-activated protein kinase (AMPK) activation, inhibition of the mammalian target of rapamycin (mTOR) activity and protein synthesis, induction of apoptosis and autophagy by p53 and p21, and decreased blood insulin level have been suggested as direct anti-cancer mechanisms of metformin. Research has shown that PCa development and progression are associated with metabolic syndrome and its components. Therefore, reduction in the risk of PCa and improvement in survival in metformin users may be the results of the direct anti-cancer mechanisms of the drug or the secondary effects from improvement of metabolic syndrome. In contrast, some research has suggested that there is no association between metformin use and PCa incidence or survival. In this comprehensive review, we summarize updated evidence on the relationship between metformin use and oncological effects in patients with PCa. We also highlight ongoing clinical trials evaluating metformin as an adjuvant therapy in novel drug combinations in various disease settings. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

16 pages, 775 KiB

Open AccessReview

Significance of Metformin Use in Diabetic Kidney Disease

by Daiji Kawanami, Yuichi Takashi and Makito Tanabe

Int. J. Mol. Sci. 2020, 21(12), 4239; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms21124239 - 14 Jun 2020

Cited by 37 | Viewed by 9438

Abstract

Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D). Based on its various pharmacologic actions, the renoprotective effects of metformin have been extensively studied. A series of experimental studies demonstrated that metformin attenuates diabetic kidney [...] Read more.

Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D). Based on its various pharmacologic actions, the renoprotective effects of metformin have been extensively studied. A series of experimental studies demonstrated that metformin attenuates diabetic kidney disease (DKD) by suppressing renal inflammation, oxidative stress and fibrosis. In clinical studies, metformin use has been shown to be associated with reduced rates of mortality, cardiovascular disease and progression to end-stage renal disease (ESRD) in T2D patients with chronic kidney disease (CKD). However, metformin should be administered with caution to patients with CKD because it may increase the risk of lactic acidosis. In this review article, we summarize our current understanding of the safety and efficacy of metformin for DKD. Full article

(This article belongs to the Special Issue Tissue-Specific Direct and Indirect Effects of Metformin and Its Application)

► Show Figures

Figure 1

Journal Menu

Journal Browser

Tissue-Specific Direct and Indirect Effects of Metformin and Its Application

Share This Special Issue

Special Issue Editor

Special Issue Information

Published Papers (9 papers)

Research

Review

Further Information

Guidelines

MDPI Initiatives

Follow MDPI